"We really try to limit the amount of tissue we resect and what we do in patients who've had radiation," says Amy E. Krambeck, MD. In this video, Amy E. Krambeck, MD, discusses patient selection for ...

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel ...

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23 ...

18F-DCFPyL PET/CT shows high detection rates in biochemically recurrent prostate cancer with low PSA levels, suggesting its utility in early metastatic disease identification. The study included 129 ...

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

"Sometimes, there is more than a single answer to a question; this certainly applies to patients with benign prostatic disease," writes Gopal H. Badlani, MD. The Society of Benign Prostatic Disease ...

Hear insights from experts on key trial data presented at ASCO GU 2025. In this video, Urology Times® highlights 5 interviews on key trial data presented at the 2025 American Society of Clinical ...

What advice do you have for urologists considering the adoption of newer treatment modalities for BCG-unresponsive NMIBC, especially in light of the positive clinical trial data?

The CLEAR trial demonstrated lenvatinib plus pembrolizumab's superior efficacy over sunitinib in advanced renal cell carcinoma, with robust response rates and significant tumor shrinkage. Sustained ...

Panelists discuss how PD-L1 inhibitors such as durvalumab and sasanlimab represent a promising frontier in non–muscle-invasive bladder cancer (NMIBC) treatment. These immunotherapies work by ...

Nivolumab plus cabozantinib significantly improved PFS, OS, and ORR compared to sunitinib in advanced RCC patients. The combination therapy showed a median PFS of 16.4 months versus 8.3 months for ...

"I think this is the next step for testing the clinical activity of this agent," says David A. Braun, MD, PhD. In this video, David A. Braun, MD, PhD, describes background and design of the phase 2 ...